Scholarlink

Cervical cancer exhibits age-related differences in incidence and outcomes, but the molecular basis for these variations remains unclear. This study examines Differentially Expressed Genes (DEGs) across five age groups (20–29, 30–39, 40–49, 50–59, and 60–69 years). The analysis employs RNA-seq data from 196 cervical biopsy samples (147 tumors, 49 controls) of early-stage cervical cancer (FIGO IA–IIA) obtained from TCGA-CESC and GTEx datasets. The analysis filters low-expressed genes, corrects batch effects with ComBat-seq, and uses DESeq2 to find DEGs. This approach identifies novel DEGs with large expression differences (|log2 fold change| >10), including age-specific, multi-group shared, and pan-age group genes. The identified age-specific DEGs (N = 51) show a median log2 expression of 8.84 (IQR: 6.54–11.3) in tumors versus 0.93 (IQR: 0.74–1.39) in controls. These results reveal molecular differences by age and support targeted therapies and age-specific screening.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Age-Associated Differential Gene Expression in Early-Stage Cervical Cancer Patients

  • 会议论文

  • 发表日期：

    2026年

查看全文
  • Praveen Kumar Govarthan,
  • Jac Fredo Agastinose Ronickom,
  • Ramakrishnan Swaminathan

摘要

Cervical cancer exhibits age-related differences in incidence and outcomes, but the molecular basis for these variations remains unclear. This study examines Differentially Expressed Genes (DEGs) across five age groups (20–29, 30–39, 40–49, 50–59, and 60–69 years). The analysis employs RNA-seq data from 196 cervical biopsy samples (147 tumors, 49 controls) of early-stage cervical cancer (FIGO IA–IIA) obtained from TCGA-CESC and GTEx datasets. The analysis filters low-expressed genes, corrects batch effects with ComBat-seq, and uses DESeq2 to find DEGs. This approach identifies novel DEGs with large expression differences (|log2 fold change| >10), including age-specific, multi-group shared, and pan-age group genes. The identified age-specific DEGs (N = 51) show a median log2 expression of 8.84 (IQR: 6.54–11.3) in tumors versus 0.93 (IQR: 0.74–1.39) in controls. These results reveal molecular differences by age and support targeted therapies and age-specific screening.